Pressor Agents, Pure Inotropes, Mixed Function Agents

  • Paul AnayaEmail author
  • Tracy E. Macaulay
Part of the Contemporary Cardiology book series (CONCARD)


Vasoactive pharmacologic agents play an important role in the management of shock. These agents can be broadly categorized as vasodilators, vasopressors, and inotropic agents. Each of these agents can variably affect myocardial preload, afterload, and inotropy to enhance cardiac performance. The choice of these agents is largely dependent on the clinical circumstances faced and a working knowledge of the pharmacologic and hemodynamic effects unique to these agents. This chapter presents the most common vasoactive pharmacologic agents used in clinical practice for the treatment of cardiogenic shock. The hemodynamic as well as pharmacologic properties of these agents are reviewed in order to provide a basis on which a practical understanding of their effects can develop and guide medical decision-making.


Preload Afterload Pressure-volume relation Elastance Inotrope Vasopressor Vasoconstriction Vasodilatation Tachyphylaxis Shock 


  1. 1.
    Tuchschmidt J, Fried J, Astiz M, et al. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest. 1992;102(1):216–20.CrossRefGoogle Scholar
  2. 2.
    Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence based approach. Am Heart J. 2001;142(3):393–401.CrossRefGoogle Scholar
  3. 3.
    Taylor RR, Covell JS, Sonnenblick EH, Ross J Jr. Dependence of ventricular distensibility on filling of the opposite ventricle. Am J Phys. 1967;213(3):711–8.CrossRefGoogle Scholar
  4. 4.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.CrossRefGoogle Scholar
  5. 5.
    Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52(3):200–7.CrossRefGoogle Scholar
  6. 6.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343(8906):1115–22.Google Scholar
  7. 7.
    Flather M, Pipilis A, Collins R, et al. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators. Eur Heart J. 1994;15(5):608–19.CrossRefGoogle Scholar
  8. 8.
    Opie L, Gersch B, editors. Drugs for the heart. 6th ed. Philadelphia: Elsevier; 2005. p. 161–2.Google Scholar
  9. 9.
    Dell’Italia LJ, Starling MR, Blumhardt R, et al. Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction. Circulation. 1985;72(6):1327–35.CrossRefGoogle Scholar
  10. 10.
    Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock. A randomized clinical trial. JAMA. 2013;310(16):1683–91.CrossRefGoogle Scholar
  11. 11.
    Publication committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA. 2002;287(15):1531–40.Google Scholar
  12. 12.
    Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39(5):798–803.CrossRefGoogle Scholar
  13. 13.
    O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.CrossRefGoogle Scholar
  14. 14.
    Overgaard CB, Dzavik V. Inotropes and Vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118:1047–56.Google Scholar
  15. 15.
    Leier CV, Heban PT, Huss P, et al. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation. 1978;58(3 pt 1):466–75.CrossRefGoogle Scholar
  16. 16.
    Unverferth DV, Magorien RD, Lewis RP, et al. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1980;100(5):622–30.CrossRefGoogle Scholar
  17. 17.
    Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354(9190):1625–33.CrossRefGoogle Scholar
  18. 18.
    Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7.CrossRefGoogle Scholar
  19. 19.
    Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001;81:141–9.CrossRefGoogle Scholar
  20. 20.
    Kumar A, Choudhary G, Antonio C, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J. 2001;142:512–5.CrossRefGoogle Scholar
  21. 21.
    Nieminem MS, Fruhwald S, Heunks LMA, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227–45.Google Scholar
  22. 22.
    Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low output syndrome. Cochrane Database Syst Rev. 2018:CD009669.pub3.
  23. 23.
    Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356(9248):2139–43.CrossRefGoogle Scholar
  24. 24.
    Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORA- SEPT II Study Investigators. Am J Med. 1999;107(4):387–90.CrossRefGoogle Scholar
  25. 25.
    Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29(8):1526–31.CrossRefGoogle Scholar
  26. 26.
    Bassi G, Radermacher P, Calzia E. Catecholamines and vasopressin during critical illness. Endocrinol Metab Clin N Am. 2006;35(4):839–57.CrossRefGoogle Scholar
  27. 27.
    Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med. 2007;35(1):33–40.CrossRefGoogle Scholar
  28. 28.
    Lindner KH, Dirks B, Strohmenger HU, et al. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet. 1997;349(9051):535–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Gill Heart InstituteUniversity of KentuckyLexingtonUSA

Personalised recommendations